Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions

References

• Deeks ED. Ibrutinib: a review in chronic lymphocytic leukaemia. Drugs. 2017;77(2):225–236.
   PubMed Web of Science ®Google Scholar
• Singh SP, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):1–23.
   PubMed Web of Science ®Google Scholar
• Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nature Rev Cancer. 2014;14(4):219–232.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88.
   PubMed Web of Science ®Google Scholar
• Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–745.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nature Med. 2015;21(8):922–926.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770–778.
   PubMed Web of Science ®Google Scholar
• Noy A, De Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224–2232.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. New Engl J Med. 2015;372(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New Engl J Med. 2013;369(1):32–42.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New Engl J Med. 2014;371(3):213–223.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. New Engl J Med. 2015;373(25):2425–2437.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409–1418.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Chronic lymphocytic leukemia/small lymphocytic lymphoma (Version 1.2021). [ updated 2020 Sept 28]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cll_blocks.pdf
   Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–2506.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131(17):1910–1919.
   PubMed Web of Science ®Google Scholar
• Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–1363.
   PubMed Web of Science ®Google Scholar
• Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787–798.
   PubMed Web of Science ®Google Scholar
• Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80–87.
   PubMed Web of Science ®Google Scholar
• Mato AR, Nabhan C, Barr PM, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128(18):2199–2205.
   PubMed Web of Science ®Google Scholar
• Aarup K, Rotbain EC, Enggaard L, et al. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. Eur J Haematol. 2020;105(5):646–654.
   PubMed Web of Science ®Google Scholar
• Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–879.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Hillmen P, Ghia P, et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia [Abstract]. American Society of Clinical Oncology Annual Meeting; 2021 June 4–8; Online.
   Google Scholar
• Hillmen P, Eichhorst B, Brown J First interim analysis of alpine study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma [Abstract]. European Hematology Association Congress; 2021 June 9–17; Virtual.
   Google Scholar
• van Leeuwen RW, van Gelder T, Mathijssen RH, et al. Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15(8):e315–e326.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Hillmen P, Coutre S, et al. Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18(10):648–657.
   PubMed Web of Science ®Google Scholar
• Tomcsányi J, Nényei Z, Mátrai Z, et al. Ibrutinib, an approved tyrosine kinase inhibitor as a potential cause of recurrent polymorphic ventricular tachycardia. J Am Coll Cardiol EP. 2016;2(7):847–849.
   Google Scholar
• Wallace N, Wong E, Cooper D, et al. A case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma. Clin Case Rep. 2016;4(12):1120.
   PubMed Web of Science ®Google Scholar
• Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129(18):2581.
   PubMed Web of Science ®Google Scholar
• Madgula AS, Singh M, Almnajam M, et al. Ventricular tachycardia storm in a patient treated with ibrutinib for waldenstrom macroglobulinemia. J Am Coll Cardiol Cardiol Onc. 2020;2(3):523–526.
   Google Scholar
• Brown JR, Moslehi J, O’Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796–1805.
   PubMed Web of Science ®Google Scholar
• Pretorius L, Du X-J, Woodcock EA, et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am J Pathol. 2009;175(3):998–1009.
   PubMed Web of Science ®Google Scholar
• McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829–3830.
   PubMed Web of Science ®Google Scholar
• Ja C, De Caterina R. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–2747.
   PubMed Web of Science ®Google Scholar
• Association DwtscotEHR, Surgery EbtEAfC-T, Members ATF, et al. Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–2429.
   PubMed Web of Science ®Google Scholar
• Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49(1):49–56.
   PubMed Web of Science ®Google Scholar
• Ganatra S, Sharma A, Shah S, et al. Ibrutinib-associated atrial fibrillation. J Am Coll Cardiol EP. 2018;4(12):1491–1500.
   Google Scholar
• Mock J, Kunk P, Palkimas S, et al. Risk of major bleeding with ibrutinib. Clin Lymphoma Myeloma Leuk. 2018;18(11):755–761.
   PubMed Web of Science ®Google Scholar
• Winqvist M, Asklid A, Andersson P, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica. 2016;101(12):1573–1580.
   PubMed Web of Science ®Google Scholar
• Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015;29(4):783.
   PubMed Web of Science ®Google Scholar
• Quek L, Bolen J, Watson S. A role for Bruton’s tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol. 1998;8(20):1137–S1.
   PubMed Web of Science ®Google Scholar
• Atkinson B, Ellmeier W, Watson S. Tec regulates platelet activation by GPVI in the absence of Btk. Blood. 2003;102(10):3592.
   PubMed Web of Science ®Google Scholar
• Liu J, Fitzgerald ME, Berndt MC, et al. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood. 2006;108(8):2596–2603.
   PubMed Web of Science ®Google Scholar
• Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124(26):3991.
   PubMed Web of Science ®Google Scholar
• Jones JA, Hillmen P, Coutre S, et al. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Brit J Haematol. 2017;178(2):286–291.
   PubMed Web of Science ®Google Scholar
• Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23(1):145–153.
   PubMed Web of Science ®Google Scholar
• Wadhwa PD, Morrison VA, editors. Infectious complications of chronic lymphocytic leukemia. Semin Oncol, 2006. Elsevier. DOI:https://doi.org/10.1053/j.seminoncol.2005.12.013
   Google Scholar
• Tillman B, Pauff J, Satyanarayana G, et al. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur J Haematol. 2018;100(4):325–334.
   PubMed Web of Science ®Google Scholar
• Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213–2219.
   PubMed Web of Science ®Google Scholar
• Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833–843. e5.
   PubMed Web of Science ®Google Scholar
• Rogers KA, Mousa L, Zhao Q, et al. Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. Leukemia. 2019;33(10):2527–2531.
   PubMed Web of Science ®Google Scholar
• Varughese T, Taur Y, Cohen N, et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis. 2018;67(5):687–692.
   PubMed Web of Science ®Google Scholar
• Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955–1959.
   PubMed Web of Science ®Google Scholar
• Herbst S, Shah A, Mazon Moya M, et al. Phagocytosis‐dependent activation of a TLR 9–BTK–calcineurin–NFAT pathway co‐ordinates innate immunity to Aspergillus fumigatus. EMBO Mol Med. 2015;7(3):240–258.
   PubMed Web of Science ®Google Scholar
• Bercusson A, Colley T, Shah A, et al. Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. Blood. 2018;132(18):1985–1988.
   PubMed Web of Science ®Google Scholar
• Montserrat E. When CLL meets COVID-19. Blood. 2020;136(10):1115–1116.
   PubMed Web of Science ®Google Scholar
• Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134–1143.
   PubMed Web of Science ®Google Scholar
• Scarfo L, Chatzikonstantinou T, Rigolin G, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34(9):2354–2363.
   PubMed Web of Science ®Google Scholar
• Bhaskar S, Sinha A, Banach M, et al. Cytokine storm in COVID-19—immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper. Front Immunol. 2020;11:1648.
   PubMed Web of Science ®Google Scholar
• Thibaud S, Tremblay D, Bhalla S, et al. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19. Brit J Haematol. 2020;190(2):e73–e76.
   PubMed Web of Science ®Google Scholar
• Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135(21):1912–1915.
   PubMed Web of Science ®Google Scholar
• Reda G, Noto A, Cassin R, et al. Reply to “CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report” Analysis of six hematological centers in Lombardy. Leukemia. 2020;34(9):2531–2532.
   PubMed Web of Science ®Google Scholar
• Pleyer C, Ali MA, Cohen JI, et al. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood. 2021;137(2):185–189.
   PubMed Web of Science ®Google Scholar
• Roeker LE, Knorr DA, Thompson MC, et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia. epub ahead of print on 2021 May 13. DOI:https://doi.org/10.1038/s41375-021-01270-w
   Google Scholar
• Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012;30(23):2820.
   PubMed Web of Science ®Google Scholar
• Barrientos JC, Burger JA, Byrd JC, et al. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leuk Lymphoma. 2019;60(4):1000–1005.
   PubMed Web of Science ®Google Scholar
• Rossi D, Gaidano G. Lymphocytosis and ibrutinib treatment of CLL. Blood J Am Soc Hematol. 2014;123(12):1772–1774.
   Google Scholar
• Herman SE, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014;28(11):2188–2196.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810–1817.
   PubMed Web of Science ®Google Scholar
• Parmar S, Patel K, Pinilla-Ibarz J. Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. P&T. 2014;39(7):483–519.
   PubMedGoogle Scholar
• de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Persp. 2015;3:4.
   Web of Science ®Google Scholar
• Tapaninen T, Olkkola AM, Tornio A, et al. Itraconazole Increases Ibrutinib Exposure 10‐Fold and Reduces Interindividual Variation—A Potentially Beneficial Drug‐Drug Interaction. Clin Transl Sci. 2020;13(2):345–351.
   PubMed Web of Science ®Google Scholar
• de Jong J, Hellemans P, De Wilde S, et al. A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies. Leuk Lymphoma. 2018;59(12):2888–2895.
   PubMed Web of Science ®Google Scholar
• Yasu T, Momo K, Kuroda S, et al. Fluconazole Increases Ibrutinib Concentration. Am J Ther. 2020;27(6):e620–e621.
   PubMed Web of Science ®Google Scholar
• Finnes HD, Chaffee KG, Call TG, et al. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma. 2017;58(6):1376–1383.
   PubMed Web of Science ®Google Scholar
• Parikh SA, Achenbach SJ, Call TG, et al. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Med. 2020;9(10):3390–3399.
   PubMed Web of Science ®Google Scholar
• Ohyama K, Nakajima M, Suzuki M, et al. Inhibitory effects of amiodarone and its N‐deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol. 2000;49(3):244–253.
   PubMed Web of Science ®Google Scholar
• Lund M, Petersen TS, Dalhoff KP. Clinical implications of P-glycoprotein modulation in drug–drug interactions. Drugs. 2017;77(8):859–883.
   PubMed Web of Science ®Google Scholar
• Chai KL, Rowan G, Seymour JF, et al. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. Leuk Lymphoma. 2017;58(12):2811–2814.
   PubMed Web of Science ®Google Scholar
• Boriani G, Corradini P, Cuneo A, et al. Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding. Hematol Oncol. 2018;36(4):624–632.
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–1507.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration [Internet]. [revised 2018 Feb]. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210563s000lbl.pdf
   Google Scholar
• Thompson PA, Lévy V, Tam CS, et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Brit J Haematol. 2016;175(3):462–466.
   PubMed Web of Science ®Google Scholar
• De Weerdt I, Koopmans SM, Kater AP, et al. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica. 2017;102(10):1629.
   PubMed Web of Science ®Google Scholar
• Lasica M, Tam CS. Management of ibrutinib toxicities: a practical guide. Curr Hematol Malig Rep. 2020;15:177–186.
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100.
   PubMed Web of Science ®Google Scholar
• Aguilar C. Ibrutinib-related bleeding: pathogenesis, clinical implications and management. Blood Coag Fibrinolysis. 2018;29(6):481–487.
   PubMed Web of Science ®Google Scholar
• Tadmor T, Welslau M, Hus I. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2018;11(1):57–70.
   PubMed Web of Science ®Google Scholar
• Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology. 2008;2008(1):450–456.
   Google Scholar
• Maffei R, Maccaferri M, Arletti L, et al. Immunomodulatory effect of ibrutinib: reducing the barrier against fungal infections. Blood Rev. 2020;40:100635.
   PubMed Web of Science ®Google Scholar
• Chen Q, Jain N, Ayer T, et al. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States.J. Clin Oncol. 2017;35(2):166.
   Web of Science ®Google Scholar
• Shanafelt TD, Borah BJ, Finnes HD, et al. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Clin Pract. 2015;11(3):252–258.
   Google Scholar
• Dusetzina S, Winn A, Abel G, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306–311.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Girmenia C, Brüggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221–3230.
   PubMed Web of Science ®Google Scholar
• Mellinghoff SC, Panse J, Alakel N, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol. 2018;97(2):197–207.
   PubMed Web of Science ®Google Scholar
• Sharman J, Egyed M, Jurczak W, editors. Acalabrutinib±obinutuzumab vs obinutuzumab+ chlorambucil in treatment-naïve chronic lymphocytic leukemia: ELEVATE-TN 4-year follow-up [Abstract]. American Society of Clinical Oncology Annual Meeting; 2021 June 4–8; Online.
   Google Scholar
• Kater P, editor Fixed-duration ibrutinib plus venetoclax (I+ V) versus chlorambucil plus obinutuzumab (Clb+ O) for first-line treatment of chronic lymphocytic leukemia (CLL): primary analysis of the phase 3 GLOW study [Abstract]. European Hematology Association Congress; 2021 June 9–17; Virtual.
   Google Scholar
• Chen LS, Bose P, Cruz ND, et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018;132(21):2249–2259.
   PubMed Web of Science ®Google Scholar